ArticleFrontiers in cellular and infection microbiology2025
EBUS-TBNA needle rinse fluid: a superior specimen for the molecular diagnosis of intrathoracic lymph node tuberculosis.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate EBUS-TBNA needle rinse fluid versus biopsy tissue for molecular diagnosis of intrathoracic lymph node tuberculosis (TB). Methods: Retrospective analysis of 63 patients with intrathoracic lymph node TB undergoing EBUS-TBNA (2018-2024). Rinse fluid and biopsy tissue were tested via TB-DNA (n=32) and Xpert MTB/RIF (n=31); positivity rates compared. Results: The study cohort had a median age of 31 years (interquartile range: 25-50.1 years), with 57.1% (36/63) being male. The most frequently sampled lymph node stations were subcarinal (station 7, 82.5%) and right lower mediastinal (station 4R, 66.7%). Clinically, 82.5% (52/63) of patients had concomitant pulmonary TB, while 17.5% (11/63) presented with isolated intrathoracic lymph node TB. For TB-DNA detection, the positivity rate of rinse fluid (71.9%, 23/32) was significantly higher than that of biopsy tissue (46.9%, 15/32; χ²=4.146, P = 0.042). Similarly, the Xpert MTB/RIF assay showed a higher positivity rate in rinse fluid (77.4%, 24/31) compared to tissue (41.9%, 13/31; χ²=8.11, P = 0.004). Conclusions: EBUS-TBNA rinse fluid demonstrates higher sensitivity than biopsy tissue for intrathoracic lymph node TB via TB-DNA/Xpert MTB/RIF. Routine rinse fluid testing improves diagnostic yield.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.